Astec LifeSciences Q1 FY27: Loss Narrows to ₹18.7 Cr, EBITDA Breakeven Achieved

Astec LifeSciences Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a consolidated total income of ₹84.3 crore, a decrease from ₹91.6 crore in the same period last year. However, Astec achieved EBITDA breakeven at ₹0.1 crore, a significant improvement from an EBITDA loss of ₹-10.5 crore in Q1 FY26. The net loss after tax narrowed to ₹-18.7 crore from ₹-33.0 crore year-on-year. Revenue from Enterprise Products grew by 41.6% to ₹51.8 crore, while revenue from Contract Manufacturing & New Products declined by 41.8% to ₹31.8 crore. The Chairperson attributed the EBITDA improvement to a favorable product mix, improved margins, and enhanced capacity utilization, despite the overall revenue dip.